ConductScience.org, home
Drug-Targeted Alerts for Acute Kidney Injury
API referenceFor AI assistants

Trial · NCT02771977

Outcomes14

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

1 to 14 of 14

Download this page as JSON
TypeOutcomeTime framePopulationUnitsMeasured as
PRIMARYPercentage of Patients With Progression of AKI OR Dialysis OR Death14 days from RandomizationParticipantsCOUNT_OF_PARTICIPANTS
SECONDARYPercentage of Patients for Whom Any One of the Targeted Medications is DiscontinuedAssessed within 24 hours from randomizationParticipantsCOUNT_OF_PARTICIPANTS
SECONDARY14- Day Mortality RateAssessed from date of randomization to date of death from any cause, within 14 days of randomizationParticipantsCOUNT_OF_PARTICIPANTS
SECONDARYInpatient Mortality RateAssessed from point of randomization to the date of death from any cause during the end of current index hospitalization, up to 365 daysParticipantsCOUNT_OF_PARTICIPANTS
SECONDARYPercentage of Patients Who Receive Dialysis Within 14 Days of RandomizationAssessed from point of randomization to date of first documented dialysis order, within 14 days of randomizationParticipantsCOUNT_OF_PARTICIPANTS
SECONDARYPercentage of Patients on Inpatient DialysisAssessed from point of randomization to the date of first documented dialysis order during index hospitalization, up to 365 daysParticipantsCOUNT_OF_PARTICIPANTS
SECONDARYPercentage of Patients Discharged on DialysisAssessed at the point of discharge from index hospitalization, up to 365 days post randomizationParticipantsCOUNT_OF_PARTICIPANTS
SECONDARYPercentage of Patients With AKI Progression From Stage 1 to Stage 2Assessed from date of randomization to date of documented AKI progression, within 14 days of randomizationPopulation analyzed represents the number of subjects with AKI Stage 1 upon enrollment.ParticipantsCOUNT_OF_PARTICIPANTS
SECONDARYPercentage of Patients With AKI Progression From Stage 2 to Stage 3Assessed from date of randomization to date of documented AKI progression, within 14 days of randomizationAnalyzed population includes subjects with Stage 1 or Stage 2 AKI upon enrollment.ParticipantsCOUNT_OF_PARTICIPANTS
SECONDARYAKI DurationAssessed from the point of randomization to the point of AKI cessation during index hospitalization, up to 365 daysdaysMEDIAN
SECONDARYReadmission RateWithin 30 days of index hospitalization dischargeParticipantsCOUNT_OF_PARTICIPANTS
SECONDARYIndex Hospitalization CostAssessed from point of randomization to the date of discharge from index hospitalization, up to 365 days post randomizationdollarsMEDIAN
SECONDARYPercentage of AKI Best Practices Achieved Per Subject During Index HospitalizationAssessed from 24 hours from randomization up to discharge of index hospitalizationParticipantsCOUNT_OF_PARTICIPANTS
SECONDARYPercentage of Subjects With Chart Documentation of AKIAssessed from time of randomization through to date of index hospitalization discharge, up to 365 days post randomizationParticipantsCOUNT_OF_PARTICIPANTS

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT02771977/outcomes

API referenceFor AI assistants